Please login to the form below

Not currently logged in
Email:
Password:

Former Novartis exec joins Genmab

Dr Judith Klimovsky becomes chief development officer

Copenhagen, Denmark-based Genmab has appointed Dr Judith Klimovsky as executive vice president and chief development officer.

Based out of the biotech's Princeton, US office, Dr Klimovsky will be responsible for the company's global product development strategy.

She joins Genmab from Novartis, where she most recently served as senior vice president and global head of oncology clinical development, having previously served as head of the global programme for cancer drug Afinitor.

Prior to this, Dr Klimovsky held director-level positions at Merck & Co in the US, and Bristol-Myers Squibb in South America.

Jan van de Winkel, Genmab's chief executive, said: “We are very pleased to welcome Judith to Genmab.

“She has a strong track record and skills in cancer drug development which will further strengthen the company as we build a winning team to continue our success in the future on the road to becoming a sustainably profitable biotech company.

“With Judith heading our product development efforts we will be able to bring forward truly differentiated products that have the potential to transform the treatment of cancer and provide great benefits to patients and their families in the future.”

10th February 2017

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Lucid Group Communications Limited

WE’RE ON A MISSION To enhance patients’ lives through communication that changes behaviour and improves patient health outcomes....

Latest intelligence

China’s clinical trial shake-up
As many of the obstacles to running clinical trials in China fall away, the country is proving to be a better research location...
Alzheimer’s disease – is Europe prepared if a breakthrough treatment becomes available?
Healthcare leaders in the European Union should begin preparing for a breakthrough now...
The UK’s new five-year pricing agreement
Pharma has agreed to capped growth again - in exchange for uptake promises...

Infographics